Navigation Links
Protect Pharma Sells Patent Portfolio to Grunenthal GmbH
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced today that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see Protect's programs are innovative and promising enough to attract someone like Grunenthal, a leader in pain drug discovery and research."

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.

About Protect Pharmaceuticals Corporation.

Based in Princeton, New Jersey, Protect (OTC Bulletin Board: PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit www.protectpharm.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects.  These statements are subject to various risks and uncertainties.  Actual results could differ materially from those currently anticipated due to a number of factors.  The information set forth herein should be read in light of such risks and uncertainties.  The Company assumes no duty or obligation to update these statements at any future date.


'/>"/>
SOURCE Protect Pharmaceutical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
2. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
5. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
6. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
7. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
8. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
9. Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
Breaking Medicine News(10 mins):